US5326764A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the treatment of hyperproliferative disorders
Assignee: Yale University
•
Filing: 1993-06-16
•
Granted: 1994-07-05
•
Expires: 2013-06-16
Abstract
Abstract The present invention provides new methods for the treatment of hyperproliferative disorders of skin epidermal cells, particularly psoriasis, by administering 5-fluorouracil and dipyridamole, with one or both agents being administered topically at the site of the hyperproliferative disease.
Inventors
- 👤 Leonard M. Milstone
- 👤 Pauline M. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 10:42
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/66; A61K31/70
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
105 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the dipyridamole is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the 5-fluorouracil is administered orally or by injection.
Claim 2
Independent Claim
105 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the dipyridamole is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the 5-fluorouracil is administered orally or by injection.
Claim 3
Dependent Claim
22 words
The method according to claim 1 wherein the 5-fluorouracil is orally administered in an amount between about 5 and about 50 mg/week.
Claim 4
Independent Claim
105 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the 5-fluorouracil is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the dipyridamole is administered orally or by injection.
Claim 5
Independent Claim
105 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the 5-fluorouracil is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the dipyridamole is administered orally or by injection.
Claim 6
Independent Claim
123 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the dipyridamole is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the 5-fluorouracil is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %.
Claim 7
Independent Claim
123 words
A method for the treatment of hyperproliferative disorders of skin epidermal cells which comprises the concurrent administration to a patient of an efficacious amount of an inhibitor of the de novo pathway in DNA synthesis and an efficacious amount of an inhibitor of the salvage pathway in DNA synthesis, wherein the inhibitor of the de novo pathway is 5-fluorouracil and the inhibitor of the salvage pathway is dipyridamole, wherein the dipyridamole is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %, and wherein the 5-fluorouracil is administered topically at the site of the hyperproliferative disease and is applied at a concentration between about 0.1 and about 5 wt. %.
Claim 8
Dependent Claim
15 words
The method according to claim 1 wherein the hyperproliferative disorder of epidermal cells is psoriasis.
Claim 9
Dependent Claim
15 words
The method according to claim 2 wherein the hyperproliferative disorder of epidermal cells is psoriasis.
Claim 10
Dependent Claim
15 words
The method according to claim 3 wherein the hyperproliferative disorder of epidermal cells is psoriasis.
Claim 11
Dependent Claim
15 words
The method according to claim 4 wherein the hyperproliferative disorder of epidermal cells is psoriasis.
References Cited (Backward Citations)
US5242921A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-07-04 | 1998-01-03 | 1998-07-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-07-04 | 2002-01-03 | 2002-07-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-07-04 | 2006-01-03 | 2006-07-05 | $7700.00 | Window Closed / Lapsed |